EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

AMPK inhibitor, compound C, inhibits coronavirus replication in vitro

Minsu Jang, Rackhyun Park, Ayane Yamamoto, Yea-In Park, Yeonjeong Park, Siyun Lee, Junsoo Park iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0292309 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Minsu Jang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biological Science and Technology, Yonsei University, Wonju, Republic of Korea. Hauptthemen laut MEDLINE: Antiviral Agents, Coronavirus OC43, Human. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The coronavirus disease (COVID-19) pandemic has resulted in more than six million deaths by October 2022. Vaccines and antivirals for severe acute respiratory syndrome coronavirus 2 are now available; however, more effective antiviral drugs are required for effective treatment. Here, we report that a potent AMP-activated protein kinase (AMPK) inhibitor, compound C/dorsomorphin, inhibits the replication of the human coronavirus OC43 strain (HCoV-OC43). We examined HCoV-OC43 replication in control and AMPK-knockout (KO) cells and found that the virus replication decreased in AMPK-KO cells. Next, we examined the effect of the AMPK inhibitor, compound C on coronavirus replication. Compound C treatment efficiently inhibited the replication and decreased the coronavirus-induced cytotoxicity, further inhibiting autophagy. In addition, treatment with compound C in combination with chloroquine synergistically inhibited coronavirus replication. These results suggest that compound C can be considered as a potential drug candidate for COVID-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCoronavirus OC43, HumanHumansAMP-Activated Protein KinasesPyrazolesVirus ReplicationPyrimidines

Substanzen

AMP-Activated Protein KinasesAntiviral AgentsPyrazolesdorsomorphinPyrimidines

Autor:innen und Institutionen

  • Division of Biological Science and Technology, Yonsei University, Wonju, Republic of Korea.
  • Department of Life Science, Yong-In University, Yongin, Republic of Korea.

ORCID-Profile: Junsoo Park

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Jang, M., Park, R., Yamamoto, A., Park, Y. I., Park, Y., Lee, S., & Park, J. (2023). AMPK inhibitor, compound C, inhibits coronavirus replication in vitro. PLOS ONE. https://doi.org/10.1371/journal.pone.0292309

Vancouver

Jang M, Park R, Yamamoto A, Park YI, Park Y, Lee S, et al. AMPK inhibitor, compound C, inhibits coronavirus replication in vitro. PLOS ONE. 2023. doi:10.1371/journal.pone.0292309

BibTeX
@article{Jang2023,
  author = {Jang, Minsu and Park, Rackhyun and Yamamoto, Ayane and Park, Yea-In and Park, Yeonjeong and Lee, Siyun and Park, Junsoo},
  title = {AMPK inhibitor, compound C, inhibits coronavirus replication in vitro},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0292309}
}
Kostenlos starten →